Ticker Details
Actinium Pharmaceuticals, Inc Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's product portfolio includes Iomab-B and Actimab-A.
IPO Date:	January 1, 2003
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$35.77M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.15 | 3.48%
Avg Daily Range (30 D):	$0.03 | 2.62%
Avg Daily Range (90 D):	$0.04 | 2.86%

Institutional Daily Volume
Avg Daily Volume:	.21M
Avg Daily Volume (30 D):	.11M
Avg Daily Volume (90 D):	.13M

Trade Size
Avg Trade Size (Sh.):	93
Avg Trade Size (Sh.) (30 D):	234
Avg Trade Size (Sh.) (90 D):	229

Institutional Trades
Total Institutional Trades:	47
Avg Institutional Trade:	$1.86M
Avg Institutional Trade (30 D):	$2.2M
Avg Institutional Trade (90 D):	$2.2M
Avg Institutional Trade Volume:	.24M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.11M
Avg Closing Trade (30 D):	$3.87M
Avg Closing Trade (90 D):	$3.87M
Avg Closing Volume:	431.92K

News

Oct 17, 2025 @ 6:06 PM Targeted Alpha Therapies Market to Grow at 44% CAG... Source: Bcc Research

May 25, 2025 @ 10:07 PM המועד האחרו×Å... Source: N/A

May 25, 2025 @ 10:07 PM ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED L... Source: N/A

May 21, 2025 @ 8:00 PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman... Source: Bronstein, Gewirtz & Grossman, Llc

May 21, 2025 @ 12:00 AM ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds A... Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.09	$-.19	$-1.09
Diluted EPS	$-1.09	$-.19	$-1.09
Revenue	$.09M	$M	$.09M
Gross Profit
Net Income / Loss	$-33.89M	$-5.94M	$-33.89M
Operating Income / Loss	$-36.25M	$-6.41M	$-36.25M
Cost of Revenue
Net Cash Flow	$-24.9M	$-24.9M	$-24.9M
PE Ratio

Splits
Aug 11, 2020	1:30